Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn about the safety of Travoprost Ophthalmic Topical
Cream and how well it works in lowering high intraocular pressure (IOP) in patients with
open-angle glaucoma (OAG) or ocular hypertension (OHT).
A low dose, medium dose and high dose of Travoprost Ophthalmic Topical Cream will be compared
to timolol maleate ophthalmic solution, 0.5% and to travoprost ophthalmic solution, 0.004%.